These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 14698595)

  • 1. Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery.
    Stoner CL; Cleton A; Johnson K; Oh DM; Hallak H; Brodfuehrer J; Surendran N; Han HK
    Int J Pharm; 2004 Jan; 269(1):241-9. PubMed ID: 14698595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
    Cai H; Stoner C; Reddy A; Freiwald S; Smith D; Winters R; Stankovic C; Surendran N
    Int J Pharm; 2006 Feb; 308(1-2):133-9. PubMed ID: 16352407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates.
    Mandagere AK; Thompson TN; Hwang KK
    J Med Chem; 2002 Jan; 45(2):304-11. PubMed ID: 11784135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model.
    Paixão P; Gouveia LF; Morais JA
    Int J Pharm; 2012 Jun; 429(1-2):84-98. PubMed ID: 22449410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties.
    Yang Z; Zadjura LM; Marino AM; D'Arienzo CJ; Malinowski J; Gesenberg C; Lin PF; Colonno RJ; Wang T; Kadow JF; Meanwell NA; Hansel SB
    J Pharm Sci; 2010 Apr; 99(4):2135-52. PubMed ID: 19780144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of an ADME enabling selection and visualization tool for drug discovery.
    Stoner CL; Gifford E; Stankovic C; Lepsy CS; Brodfuehrer J; Prasad JV; Surendran N
    J Pharm Sci; 2004 May; 93(5):1131-41. PubMed ID: 15067690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.
    Gertz M; Harrison A; Houston JB; Galetin A
    Drug Metab Dispos; 2010 Jul; 38(7):1147-58. PubMed ID: 20368326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of in vitro metabolic stability for rapid selection of compounds in early discovery based on their expected hepatic extraction ratios.
    Lau YY; Krishna G; Yumibe NP; Grotz DE; Sapidou E; Norton L; Chu I; Chen C; Soares AD; Lin CC
    Pharm Res; 2002 Nov; 19(11):1606-10. PubMed ID: 12458665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance.
    Huang L; Berry L; Ganga S; Janosky B; Chen A; Roberts J; Colletti AE; Lin MH
    Drug Metab Dispos; 2010 Feb; 38(2):223-31. PubMed ID: 19875499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [High throughput screening of pharmacokinetics and metabolism in drug discovery (II)--investigation on in vitro and in vivo correlation in drug metabolism screening].
    Komura H; Matsuda K; Shigemoto Y; Kawahara I; Ano R; Murayama Y; Moriwaki T; Yoshida NH
    Yakugaku Zasshi; 2005 Jan; 125(1):131-9. PubMed ID: 15635284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Metabolic Stability and Permeability of Gymnemagenin and Its In Vivo Pharmacokinetic Correlation in Rats - A Pilot Study.
    Bera R; Kundu A; Sen T; Adhikari D; Karmakar S
    Planta Med; 2016 Apr; 82(6):544-50. PubMed ID: 26916641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of drug bioavailability in humans using immobilized artificial membrane phosphatidylcholine column chromatography and in vitro hepatic metabolic clearance.
    Shin BS; Yoon CH; Balthasar JP; Choi BY; Hong SH; Kim HJ; Lee JB; Hwang SW; Yoo SD
    Biomed Chromatogr; 2009 Jul; 23(7):764-9. PubMed ID: 19296531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction.
    Liu F; Zhuang X; Yang C; Li Z; Xiong S; Zhang Z; Li J; Lu C; Zhang Z
    Biopharm Drug Dispos; 2014 Jul; 35(5):296-307. PubMed ID: 24647883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
    Masimirembwa CM; Bredberg U; Andersson TB
    Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.
    Ito K; Houston JB
    Pharm Res; 2004 May; 21(5):785-92. PubMed ID: 15180335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
    Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
    Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds.
    Zhang T; Heimbach T; Lin W; Zhang J; He H
    J Pharm Sci; 2015 Sep; 104(9):2795-806. PubMed ID: 25690565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of oral bioavailability surrogates in the design of orally active inhibitors of rhinovirus replication.
    Stratford RE; Clay MP; Heinz BA; Kuhfeld MT; Osborne SJ; Phillips DL; Sweetana SA; Tebbe MJ; Vasudevan V; Zornes LL; Lindstrom TD
    J Pharm Sci; 1999 Aug; 88(8):747-53. PubMed ID: 10430536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance.
    Fagerholm U
    J Pharm Pharmacol; 2007 Jun; 59(6):803-28. PubMed ID: 17637173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.